bination of S-1 and cisplatin (CDDP) showed response rates of more than 50% against advanced gastric cancer [3] [4] [5] [6] [7] [8] . In clinical trials, CPT-11 + S-1 have shown similar high response rates of more than 50% [9] . Preoperative combination chemotherapy of S-1 with CDDP, or other drugs, has been given to patients with unresectable tumors in an attempt to reduce the size of the primary tumor and the extent of the metastases with the hope of making surgery feasible [10] .
Introduction
The detection of early-stage gastric cancer has led to an improved prognosis for patients with these tumors. However, the clinical outcome remains poor for patients with advanced gastric cancers, with peritoneal, multiple lymph node, or hematogenous metastases. The advent of new anticancer agents has enabled several novel types and regimens of chemotherapy to be tested in this patient group. S-1 (Taiho Pharmaceutical, Tokyo, Japan) is a new drug with single-agent response rates of reportedly more than 40% for advanced gastric cancer [1, 2] . S-1 has also shown good efficacy in combination chemotherapy regimens. For example, the com-Histological analysis of the biopsy specimen, removed during the endoscopy, identified a poorly differentiated adenocarcinoma. Therefore, the bulky mass adjacent to the pancreas, which had been seen on the CT scan, was diagnosed as a large lymph node metastasis from gastric cancer. Abdominal US also showed a large tumor with ascites, suggesting peritoneal dissemination. Regarding tumor markers, the serum carcinoembryonic antigen (CEA) level was 10.9 ng/ml, and the carbohydrate antigen (CA) 19-9 level was 46.1 U/ml. Based on the clinical findings and the Japanese classification of gastric carcinoma, the tumor was diagnosed as cT3(SE), cN2, H0, P1, M0, and c-stage IV [14] . Therefore, we decided that this tumor required chemotherapy.
Chemotherapy
Chemotherapy was performed using two anticancer agents, S-1 and paclitaxel. Oral S-1 (80 mg/m 2 ) was administered twice a day after meals for 2 weeks; paclitaxel (100 mg/m 2 ) was administered intravenously (i.v.) on days 1 and 15 only. The patient received two cycles of this regimen, separated by a 14-day interval. With respect to toxicity, the patient experienced grade 2 leukopenia and grade 1 nausea.
After the second course of chemotherapy, the response was assessed by imaging using endoscopy and CT scanning. Endoscopy revealed that the primary lesion was noticeably reduced, with shrinkage of the gastric wall (Fig. 2B) . Based on the CT examination, the large metastatic lymph node had disappeared, and there were no signs of ascites (Fig. 1B) . CEA and CA19-9 values had both decreased to within normal limits: 3.5 ng/ml and 21.2 U/ml, respectively.
Intraoperative findings
Prior to laparotomy, intraabdominal observation was performed using a laparoscope. Because no overt peritoneal metastases were found and the cytological examination was negative, we judged that the tumor, including the lymph node metastases, was now resectable. Following chemotherapy, the primary lesion and large lymph node metastases were dramatically reduced. A distal gastrectomy was performed, with D2 lymph node dissection. A total of 44 lymph nodes were dissected. The Billroth I method was used for reconstruction of the alimentary tract.
Histological findings
Macroscopic examination of the resected specimen showed formation of an ulcer scar at the gastric angle (Fig. 3) . Histological evidence showed that cancer cells were present, in part, in the mucosa and subserosa; and histological grading of chemotherapeutic efficacy was grade 2 (Fig. 4) . Thirty regional nodes were dissected, but no lymph node metastases were found, including the large metastasis previously located adjacent to the pancreas. A pathological diagnosis was made of pT2, N0, P0, M0, CY0, and p-stage II.
Postoperative course
One week after the gastrectomy, the patient was reoperated on for an adhesional ileus. Thereafter, his postoperative course was uneventful, and he was discharged from hospital on day 35. The patient is followed up in the outpatient clinic without further chemotherapy. He is healthy over 4 years after surgery without recurrence. 
Discussion
Recent reports have shown that S-1 is associated with good response rates when administered to patients with advanced and unresectable gastric cancer. The response rates of single-agent S-1 have been reported at 40%-50% [1, 2] . In some patients, distant metastases have disappeared after administration of single-agent S-1 [15] . Chemotherapy regimens have been devised that combined S-1 with other anticancer drugs, such as CDDP or paclitaxel; and these protocols have achieved clinical success [3] [4] [5] [6] [7] [8] [9] [10] . In 2001, we started using a combination chemotherapy regimen of S-1 and paclitaxel in the treatment of unresectable gastric cancer.
The fluoropyrimidine S-1 is an oral combined form of tegafur (FT), a prodrug of 5-fluorouracil (5-FU), and two modulators, gimeracil (CDHP) and oteracil potassium (Oxo). It owes its antitumor properties to the production of 5-FU, which is gradually converted from FT following oral administration of S-1. S-1 is designed to enhance the clinical utility of an oral fluoropyrimidine but at the same time is associated with low gastrointestinal toxicity [16, 17] . Paclitaxel binds with high affinity to microtubules and enhances tubulin polymerization. This action inhibits the normal dynamic process of the cell's microtubule network, resulting in the inhibition of mitosis and cell division [11] . The disappearance of peritoneal metastasis and the large primary tumor, which we observed in our patient, might be attributed to this inhibitory action.
The patient described in this case report had a large lymph node metastasis that was initially and mistakenly believed to be a pancreatic tumor. Furthermore, peritoneal dissemination was strongly suspected because of the presence of ascites. Even if the tumor and lymph node metastases could have been removed, the longterm survival of our patient was not expected. Therefore, we decided to attempt, first of all, to reduce the tumor load via chemotherapy. S-1 and paclitaxel are known to be associated with serious adverse effects, including bone marrow suppression, gastrointestinal symptoms, and alopecia [12, 13] . However, our patient tolerated this combination chemotherapy regimen well, and no serious adverse effect occurred.
Following two courses of chemotherapy, imaging revealed a good response. However, because it was not possible to identify the presence or absence of a tiny nodule of peritoneal metastasis by imaging, laparoscopy was performed. A laparoscopic diagnosis is essential to determine if surgery is indicated following neoadjuvant treatment. Likewise, a cytological examination of lavage fluid is important when deciding if complete resection is feasible. Based on the laparoscopic findings in our patient, we decided that complete resection was possible.
One of the most important problems facing any clinician is when to perform surgery. In our case, a complete response might have been achieved if we had continued the chemotherapy. Histological examination showed residual cancer cells in parts of the mucosa and subserosa but no lymph node metastases. At present, however, we do not know whether such tiny lesions that were resistant to the initial chemotherapy would completely disappear after further courses. In the future, we should evaluate the timing of surgery after neoadjuvant chemotherapy by studying this issue in a large number of patients. Using chemotherapy followed by surgery benefited the long-term survival of our patient. We therefore conclude that the combined chemotherapy regimen of S-1 and paclitaxel is useful as a treatment for unresectable gastric cancer. However, randomized controlled studies are necessary to evaluate fully the effect of such chemotherapy.
